The PARADIGM study, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna, aims to enhance the diagnosis and treatment of genetically heterogeneous rare diseases, specifically ED and NMD. Given the increasing prevalence of genetic disorders and the growing demand for precision medicine, this study positions itself in a lucrative market. The collaboration among multiple institutions with expertise in genomics, bioinformatics, and gene therapy may lead to innovative therapeutic strategies, potentially providing a competitive edge in the rare disease space. The focus on non-coding variants, often overlooked in traditional genomic studies, could unlock new avenues for drug development and repositioning, enhancing the commercial viability of resultant therapies.